Nutra Pharma Letter to Shareholders
January 12, 2021 at 10:25 AM EST
Plantation, Florida, January 12, 2021 — OTC PR WIRE — Nutra Pharma Corporation (OTC PINK: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today that the Company’s Chief Executive Officer, Rik J Deitsch, has published a Letter to Shareholders on the Company’s website.
“The last year was a challenging one for all businesses but was certainly a very busy year at Nutra Pharma,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Regardless of the global pandemic and economic downturn, Nutra Pharma was able to create new opportunities for our products and technologies. This has provided a strong platform for real growth in 2021,” he continued. “I wanted to take this opportunity to update our shareholders and the public on the accomplishments of the last year, the status of the Company and briefly outline our goals and expectations for the coming months,” he concluded.
The letter includes some of the following accomplishments made by the Company over the past year:
The Shareholder Letter is available on the Company’s website at: https://tinyurl.com/SL-NPHC
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin®, Equine Pain-Away and Pet Pain-Away. For additional information about Nutra Pharma, visit:
This press release contains forward-looking statements. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions are intended to identify “forward-looking statements.” Actual results could differ materially from those projected in Nutra Pharma’s (“the Company”) business plan. The publishing of a letter to shareholders should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company’s filings may be accessed at the SEC’s Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.